{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Malhotra A"],"funding":["NIA NIH HHS","NHLBI NIH HHS","Eli Lilly and Company"],"pagination":["1193-1205"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11598664"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["391(13)"],"pubmed_abstract":["<h4>Background</h4>Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide may be a potential treatment.<h4>Methods</h4>We conducted two phase 3, double-blind, randomized, controlled trials involving adults with moderate-to-severe obstructive sleep apnea and obesity. Participants who were not receiving treatment with positive airway pressure (PAP) at baseline were enrolled in trial 1, and those who were receiving PAP therapy at baseline were enrolled in trial 2. The participants were assigned in a 1:1 ratio to receive either the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks. The primary end point was the change in the ap"],"journal":["The New England journal of medicine"],"pubmed_title":["Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity."],"pmcid":["PMC11598664"],"funding_grant_id":["R01 HL157985","R01 HL166485","R01 HL148436","R01 AG063925","R01 HL154926","T32 HL166127"],"pubmed_authors":["Lu Y","Wang G","Banda Elizondo R","Hartley PA","Schurholz T","Ishihara A","Herekar AA","Guo L","Fietze I","Halpern B","Taniguchi M","Sands SA","Lederer K","Lorch DG","Schwab RJ","Dunn JP","Eckert DJ","Brengle B","Herrera Marmolejo M","Santos Canani LH","Xu L","Valdez Lopez HG","Bednarik J","Schaum T","Malhotra A","Arechavaleta Granell M","Alves BB","Brinkmann MS","Gohma I","Redline S","Cercato C","Aberle J","Li X","Broyles FE","Fukushima Y","Ramirez Hernandez A","Grunstein RR","Kawano T","Hudson JD","Kiyosue A","Lillestol MJ","Prier KT","Lacey D","Liu M","Boghara H","Layle S","Bunck MC","Nevarez Ruiz LA","Azarbarzin A","Shirahama R","SURMOUNT-OSA Investigators","Palchick BA","An Z","Andry JM","Drake RS","Hang LW","Rose L","Baron M","Zolandi Crespo Hernandez M","Kerr Saraiva JF","Yang YC","Maynard JP","Alpizar Sallaza M","Karunakara R","Reis Franco D","Matoulek M","Delgado Fernandes M","Weaver TE","Chakladar S","Klokocnikova V","Deimling A","Yamasaki Y"],"additional_accession":[]},"is_claimable":false,"name":"Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.","description":"<h4>Background</h4>Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide may be a potential treatment.<h4>Methods</h4>We conducted two phase 3, double-blind, randomized, controlled trials involving adults with moderate-to-severe obstructive sleep apnea and obesity. Participants who were not receiving treatment with positive airway pressure (PAP) at baseline were enrolled in trial 1, and those who were receiving PAP therapy at baseline were enrolled in trial 2. The participants were assigned in a 1:1 ratio to receive either the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks. The primary end point was the change in the ap","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-06-02T18:02:45.836Z","creation":"2025-07-01T03:05:25.597Z"},"accession":"S-EPMC11598664","cross_references":{"pubmed":["38912654"],"doi":["10.1056/nejmoa2404881","10.1056/NEJMoa2404881"]}}